TP53 and cancer: Particularly, the occurrence of cancer-associated splice variants, MDMX-S (that possesses high affinity for p53) and MDMX-ALT2 (that lacks the p53-binding domain), has been reported upon cisplatinum treatment [29], [43], [46], [47].